Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 30, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 3, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-445438
Filed / recorded
Nov 3, 2026, 9:26 PM UTC
Added to OQRO
Nov 3, 2026, 9:30 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Rapport Therapeutics, Inc.
Issuer CIK
2012593
Ticker
RAPP
Reporting person
Third Rock Ventures V, L.P.
Relationship
Director, 10% owner
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Oct 30, 2026
Transaction code
A
Shares / units
238,095
Price per share
$21.00
Acquired / disposed
Acquired (A)
Shares owned after
6,518,620
Ownership form
Direct
Amendment
No
Footnotes from the filing
Shares acquired in a private placement pursuant to a Securities Purchase Agreement dated October 28, 2026 by and between the Issuer, Third Rock Ventures V, L.P. ("TRV V") and Third Rock Ventures VI, L.P. ("TRV VI").
These shares are directly held by TRV V. The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
7 days before resultsTraded Oct 28 · filed 2 days later
A Rapport Therapeutics director paid $79K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
7 days before resultsTraded Oct 28 · filed 2 days later
A Rapport Therapeutics director paid $20M out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
